Matinas BioPharma Holdings (NASDAQ: MTNB) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and target prices for Matinas BioPharma Holdings and Galectin Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Matinas BioPharma Holdings 0 0 3 0 3.00
Galectin Therapeutics 1 1 1 0 2.00

Matinas BioPharma Holdings presently has a consensus target price of $7.67, indicating a potential upside of 459.61%. Galectin Therapeutics has a consensus target price of $2.08, indicating a potential upside of 17.70%. Given Matinas BioPharma Holdings’ stronger consensus rating and higher possible upside, equities analysts plainly believe Matinas BioPharma Holdings is more favorable than Galectin Therapeutics.


This table compares Matinas BioPharma Holdings and Galectin Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Matinas BioPharma Holdings -8,834.65% -143.22% -79.91%
Galectin Therapeutics N/A -1,747.01% -134.48%

Earnings & Valuation

This table compares Matinas BioPharma Holdings and Galectin Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Matinas BioPharma Holdings $59,875.00 2,104.41 -$12.81 million N/A N/A
Galectin Therapeutics N/A N/A -$19.47 million ($0.61) -2.90

Matinas BioPharma Holdings has higher revenue and earnings than Galectin Therapeutics.

Institutional & Insider Ownership

11.2% of Galectin Therapeutics shares are held by institutional investors. 40.3% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


Matinas BioPharma Holdings beats Galectin Therapeutics on 7 of the 10 factors compared between the two stocks.

About Matinas BioPharma Holdings

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.

About Galectin Therapeutics

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with's FREE daily email newsletter.